Principal Street Partners LLC Purchases 8,986 Shares of AstraZeneca PLC (NASDAQ:AZN)

Principal Street Partners LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 98.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,134 shares of the company's stock after buying an additional 8,986 shares during the period. Principal Street Partners LLC's holdings in AstraZeneca were worth $1,414,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. McClarren Financial Advisors Inc. boosted its stake in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock worth $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new position in shares of AstraZeneca during the 2nd quarter worth about $26,000. Capital Performance Advisors LLP purchased a new position in shares of AstraZeneca during the 3rd quarter worth about $28,000. Pathway Financial Advisers LLC purchased a new position in shares of AstraZeneca during the 1st quarter worth about $29,000. Finally, Hobbs Group Advisors LLC purchased a new position in shares of AstraZeneca during the 2nd quarter worth about $35,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Stock Down 0.1 %

Shares of NASDAQ:AZN traded down $0.04 during trading hours on Tuesday, hitting $66.36. The company's stock had a trading volume of 4,282,968 shares, compared to its average volume of 5,327,350. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a market capitalization of $205.76 billion, a price-to-earnings ratio of 31.75, a P/E/G ratio of 1.20 and a beta of 0.47. The firm's fifty day moving average price is $72.94 and its 200 day moving average price is $77.65.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the business posted $0.87 EPS. The company's quarterly revenue was up 18.0% compared to the same quarter last year. As a group, research analysts expect that AstraZeneca PLC will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on AZN shares. TD Cowen lifted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research note on Monday, August 12th. Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. Finally, UBS Group raised shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research report on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.